China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house developed drug candidates: HRS-1780, HRS-1358, and SHR-7367. These approvals mark significant milestones in the company’s pipeline development, positioning Hengrui to advance innovative treatments for chronic kidney disease and advanced malignant tumors.
HRS-1780 Profile
HRS-1780 is an oral small-molecule drug being developed to treat chronic kidney disease (CKD). Currently, CKD is treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists, which generated global sales of USD 1.59 billion and USD 4 billion, respectively, in 2021. HRS-1780 aims to offer a new therapeutic option for this prevalent condition.
HRS-1358 Profile
HRS-1358 is designed to inhibit the proliferation of tumor cells and overcome mutation resistance of target proteins. It offers higher selectivity compared to conventional small-molecule drugs, positioning it as a potential global first-in-class candidate. This innovative approach could significantly enhance the treatment landscape for various cancers.
SHR-7367 Profile
SHR-7367 is a self-developed antibody targeting advanced malignant tumors. It works by specifically binding to tumor-related antigens and activating immune co-stimulatory molecules, thereby activating a variety of immune cells in the tumor microenvironment. Like HRS-1358, SHR-7367 is also described as a potential global first-in-class candidate, highlighting Hengrui’s commitment to pioneering new treatments.
Future Implications:
The clinical trial approvals for HRS-1780, HRS-1358, and SHR-7367 underscore Hengrui Pharmaceuticals’ dedication to advancing its R&D pipeline. These drug candidates have the potential to address significant unmet medical needs, offering new hope for patients with chronic kidney disease and advanced malignant tumors.-Fineline Info & Tech
